| Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study |
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced 24-week post-end of treatment data from Part B of the ongoing MARCH Phase 2 clinical study evaluating tobevibart and elebsiran without or with pegylated interferon alpha (PEG-IFNα) in participants with chronic hepatitis B (CHB). The study-defined primary endpoint, proportion of participants with undetectable hepatitis B surface antigen (HBsAg) at 24 weeks post-end of treatment, was achieved by 17% (3/18) and 2. |
businesswire.com |
2025-05-09 10:00:00 |
Czytaj oryginał (ang.) |
| Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment |
Vir Biotechnology, Inc.'s phase 3 ECLIPSE program for HDV, leveraging tobevibart and elebsiran, shows promise based on positive phase 2 SOLSTICE study results. The global hepatitis D market size is projected to surpass $1.05 billion by 2034. VIR-5518 and VIR-5500 are dual-masked HER2 and PSMA T-cell engagers being developed to target solid tumors; The current status of these candidates is that dose-escalation for both are ongoing. |
seekingalpha.com |
2025-05-08 19:37:09 |
Czytaj oryginał (ang.) |
| Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript |
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Mika Derynck - Executive Vice President of Therapeutic Head Oncology Conference Call Participants Gena Wang - Barclays Paul Choi - Goldman Sachs Nick Gasic - Leerink Partners Phil Nadeau - TD Cowen Patrick Trucchio - H.C. Wainwright & Co. Joseph Stringer - Needham & Company Operator Hello. |
seekingalpha.com |
2025-05-08 03:21:10 |
Czytaj oryginał (ang.) |
| Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates |
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to loss of $0.48 per share a year ago. |
zacks.com |
2025-05-07 23:20:42 |
Czytaj oryginał (ang.) |
| Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025 |
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will provide a corporate update and report financial results for the first quarter ended March 31, 2025, on May 7, 2025. The Company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on May 7, 2025. The corporate update and financial results will be provided via a press release shortly after market close and will be accessible on the News page in the Investors section of the Vir Biote. |
businesswire.com |
2025-04-30 20:05:00 |
Czytaj oryginał (ang.) |
| Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 |
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from a 24-week subgroup analysis of its ongoing Phase 2 SOLSTICE trial in chronic hepatitis delta at the upcoming European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam (The Netherlands), May 7-10. The Company will also present 24 Week post-treatment follow-up data from the MARCH Phase 2 clinical study evaluating combinations of tobevibart and elebsiran,. |
businesswire.com |
2025-04-24 13:30:00 |
Czytaj oryginał (ang.) |
| Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results |
Strategic Acquisition of Intellectual Property of BRII-179, a Wholly Owned Phase 2b Asset Capable of Combining with Multiple HBV Treatment Modalities for Cure Data from Multiple Ongoing Late-Stage Studies Reinforce Brii Bio's HBV Functional Cure Strategy of Optimized Combination Regimens to Target Patient Populations 4 Abstracts Including 2 Oral Presentations with Data from the Ongoing Phase 2 ENSURE Study at the Upcoming APASL (March 26-30) Strong Cash Reserves of US$335.7 Million to Propel Operations into 2028 Actively Seeking Partnership Opportunities for Non-HBV Programs Conference Call (English Session) Scheduled for March 31 at 8:30 PM HKT / 8:30 AM ET DURHAM, N.C. and BEIJING, China , March 21, 2025 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health across diseases with high unmet medical needs provided a corporate update today and reported its financial results for the year ended December 31, 2024. |
prnewswire.com |
2025-03-21 09:10:00 |
Czytaj oryginał (ang.) |
| Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript |
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Mika Derynck - Executive Vice President of Therapeutic Head Oncology Conference Call Participants Hang Hu - Barclays Paul Choi - Goldman Sachs Phil Nadeau - TD Cowen Alec Stranahan - Bank of America Joseph Stringer - Needham Patrick Trucchio - H.C. Wainwright & Co. Operator Hello. |
seekingalpha.com |
2025-02-27 01:22:02 |
Czytaj oryginał (ang.) |
| Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates |
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $0.86 per share a year ago. |
zacks.com |
2025-02-26 20:45:22 |
Czytaj oryginał (ang.) |
| Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results |
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2024. “2024 was a year of transformation for Vir Biotechnology as we successfully defined and executed on our renewed strategic direction, focusing our resources on our most promising programs in infectious diseases and oncology,” said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Bio. |
businesswire.com |
2025-02-26 18:05:00 |
Czytaj oryginał (ang.) |
| Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference |
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the executive team are scheduled to participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 8:50 a.m. PT / 11:50 a.m. ET in Boston, Massachusetts. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website and will be archived for 30 days. About Vir Biotech. |
businesswire.com |
2025-02-19 18:05:00 |
Czytaj oryginał (ang.) |
| Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 |
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions. |
seekingalpha.com |
2025-01-13 20:10:02 |
Czytaj oryginał (ang.) |
| Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why |
On Wednesday, Vir Biotechnology, Inc. VIR presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR-5500, which targets PSMA in metastatic castration-resistant prostate cancer (mCRPC). |
benzinga.com |
2025-01-10 16:32:21 |
Czytaj oryginał (ang.) |
| VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates |
Vir Biotechnology posts encouraging initial data from phase I studies evaluating VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors. |
zacks.com |
2025-01-09 14:45:28 |
Czytaj oryginał (ang.) |
| Vir Biotechnology: A Rocket Off Phase 1 Data |
Vir Biotechnology's recent share price rally is driven by their promising cancer program, despite their primary focus on hepatitis management. The company's market cap has surged past $1 billion, raising questions about the sustainability and justification of this valuation. The early data for their T cell engagers suggest favorable safety, with hints of efficacy and a boatload more patients in phase 1 waiting for more evaluation. |
seekingalpha.com |
2025-01-09 11:00:00 |
Czytaj oryginał (ang.) |
| Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why |
On Wednesday, Vir Biotechnology, Inc. VIR stock traded higher after the company presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR-5500, which targets PSMA in metastatic castration-resistant prostate cancer (mCRPC). |
benzinga.com |
2025-01-08 14:28:22 |
Czytaj oryginał (ang.) |
| Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC |
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome (CRS), maximum tolerated dose (MTD) not yet reached as dose escalation co. |
businesswire.com |
2025-01-08 09:45:00 |
Czytaj oryginał (ang.) |
| Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, at 4:30 p.m. PT in San Francisco, California. A live webcast of the presentation will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at www.vir.bio and will be archived there for 30 days. About. |
businesswire.com |
2024-12-18 11:30:00 |
Czytaj oryginał (ang.) |
| Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January |
VIR's is expected to report data in January from two phase 1 trials of VIR-5500 and VIR-5818, two T-cell engagers, in various cancer types. JANX recently produced promising data with JANX007, which is similar to VIR-5500, in prostate cancer. As for elebsiran and tobevibart, two treatments for hepatitis B and hepatitis delta, a phase 3 program in hepatitis delta will get underway in H1'25. |
seekingalpha.com |
2024-12-13 14:57:47 |
Czytaj oryginał (ang.) |
| Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta |
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that tobevibart and elebsiran have received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation and European Medicines Agency (EMA) Priority Medicines (PRIME) designation for the treatment of chronic hepatitis delta (CHD). The designations are supported by compelling positive safety and efficacy data from the Phase 2 SOLSTICE trial, from which the Company recently presented new data at AAS. |
businesswire.com |
2024-12-12 18:05:00 |
Czytaj oryginał (ang.) |
| Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs |
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1 T-cell engagers VIR-5818 targeting a variety of HER2-expressing solid tumors and VIR-5500 targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC) along with updates on the PRO-XTEN™ platform on January 8, 2025, at 5:00 a.m. PT / 8:00 a.m. ET. A live webcast will be available on https://investors.vir.bio/. |
businesswire.com |
2024-11-26 11:30:00 |
Czytaj oryginał (ang.) |
| Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference |
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday December 3, at 6:10 a.m. PT / 9:10 a.m. ET in Miami, Florida. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir Biotechnology website at www.vir.bio and wil. |
businesswire.com |
2024-11-25 11:30:00 |
Czytaj oryginał (ang.) |
| Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program |
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced positive results from the SOLSTICE Phase 2 clinical trial evaluating tobevibart alone, or in combination with elebsiran, in people with chronic hepatitis delta (CHD). The most-advanced and potential first-of-its-kind investigational human monoclonal antibody and siRNA combination dosed monthly achieved 100% virologic response and rapid hepatitis delta virus (HDV) RNA suppression. HDV RNA below the lower limit o. |
businesswire.com |
2024-11-18 23:15:00 |
Czytaj oryginał (ang.) |
| Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency |
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP), has issued a positive opinion on the application for orphan drug designation of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD). This opinion is based on encouraging preliminary data from the Phase 2 SOLSTICE trial. Vir Biotechnology will present 24-week data from the Phase 2 SOLSTICE trial at A. |
businesswire.com |
2024-11-18 18:05:00 |
Czytaj oryginał (ang.) |
| Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting |
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart and elebsiran, with or without pegylated interferon alfa (PEG-IFNα), in participants with chronic hepatitis B. The study demonstrated promising rates of hepatitis B surface antigen (HBsAg) loss (seroclearance) in participants with low baseline HBsAg ( |
businesswire.com |
2024-11-15 13:00:00 |
Czytaj oryginał (ang.) |
| Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off |
VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. However, VIR also pivoted to oncology, discontinuing vaccines and viral immunotherapy, and partnered with Sanofi to leverage its PRO-XTEN platform for T-cell engagers. The strategic shift includes a 25% workforce reduction, saving $50 million annually by 2025, and focuses on advancing hepatitis delta and B treatments. |
seekingalpha.com |
2024-11-05 13:29:43 |
Czytaj oryginał (ang.) |
| Vir Biotechnology, Inc. (VIR) Q3 2024 Earnings Call Transcript |
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Mark Eisner - Executive Vice President & Chief Medical Officer Jason O'Byrne - Executive Vice President & Chief Financial Officer Conference Call Participants Paul Choi - Goldman Sachs Eric Joseph - JPMorgan Mike Ulz - Morgan Stanley Gena Wang - Barclays Alec Stranahan - Bank of America Nikola Gasic - Leerink Phil Nadeau - TD Cowen Patrick Trucchio - H.C. Wainwright & Co. |
seekingalpha.com |
2024-11-01 01:12:13 |
Czytaj oryginał (ang.) |
| Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Lags Revenue Estimates |
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.56 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to loss of $1.22 per share a year ago. |
zacks.com |
2024-10-31 20:20:27 |
Czytaj oryginał (ang.) |
| Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024 |
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2024, on October 31, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on October 31, 2024. The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors. |
businesswire.com |
2024-10-17 20:30:00 |
Czytaj oryginał (ang.) |
| Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference |
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer, is scheduled to participate in a fireside chat at the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference on Tuesday, October 8, at 10:00 a.m. PT / 1:00 p.m. ET. A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at www.vir.bio and wil. |
businesswire.com |
2024-10-03 20:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 258.38% Upside in Vir Biotechnology (VIR): Can the Stock Really Move This High? |
The consensus price target hints at a 258.4% upside potential for Vir Biotechnology (VIR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-08-06 14:55:48 |
Czytaj oryginał (ang.) |
| Prediction: This Pharma Stock Will Be the Best Performer the Rest of 2024 |
24/7 Wall St. Insights Market pullbacks can make nervous investors leery of investing in industries that are speculative in nature. |
247wallst.com |
2024-08-06 13:15:34 |
Czytaj oryginał (ang.) |
| Vir Biotechnology, Inc. (VIR) Q2 2024 Earnings Call Transcript |
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Richard Lepke - Senior Director, Investor Relations Marianne De Backer - Chief Executive Officer Jennifer Towne - Executive Vice President and Chief Scientific Officer Mark Eisner - Executive Vice President and Chief Medical Officer Brent Sabatini - Chief Accounting Officer Conference Call Participants Phil Nadeau - TD Cowen Nikola Gasic - Leerink Paul Choi - Goldman Sachs Eric Joseph - J.P. Morgan Mike Ulz - Morgan Stanley Joseph Stringer - Needham & Company Alec Stranahan - Bank of America Operator Hello. |
seekingalpha.com |
2024-08-02 02:10:28 |
Czytaj oryginał (ang.) |
| Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates |
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to loss of $1.45 per share a year ago. |
zacks.com |
2024-08-01 22:51:05 |
Czytaj oryginał (ang.) |
| Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities |
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2024. “The positive preliminary SOLSTICE Phase 2 study together with the recent FDA IND clearance and Fast Track designation for tobevibart and elebsiran for the treatment of chronic hepatitis delta infection highlight the encouraging momentum we're building towards addressing the substantial unmet medical need for patients. |
businesswire.com |
2024-08-01 20:02:00 |
Czytaj oryginał (ang.) |
| Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024 |
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio. Participants may ac. |
businesswire.com |
2024-07-18 20:05:00 |
Czytaj oryginał (ang.) |
| Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis |
VIR develops medicines for infectious and viral diseases using proprietary platforms for monoclonal antibodies and T cell-based Viral Vectors. Positive Phase 2 trial results for chronic hepatitis delta highlight the company's potential to address unmet medical needs. Strategic collaborations include the Bill & Melinda Gates Foundation, Alnylam Pharmaceuticals, and Gilead Sciences. |
seekingalpha.com |
2024-07-17 20:47:26 |
Czytaj oryginał (ang.) |